Related Experiment Video
Updated: Dec 26, 2025
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
720
Leflunomide-Induced Hidradenitis Suppurativa.
Achraf Machan1, Hasna Azendour2, Hamza Toufik3
1Department of Dermatology, Mohammed V Military Hospital, Mohammed V University of Rabat, Rabat, Morocco.
Case Reports in Rheumatology
|March 10, 2020
Summary
Hidradenitis suppurativa can be drug-induced. Two rheumatoid arthritis patients developed this condition during leflunomide treatment and improved after stopping the medication.
Area of Science:
- Dermatology
- Rheumatology
- Pharmacology
Background:
- Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition affecting the pilosebaceous unit.
- HS significantly impacts patient quality of life due to its chronic and intermittent nature.
- Drug-induced HS is a rare but reported phenomenon.
Observation:
- Two female patients undergoing treatment for rheumatoid arthritis were observed.
- Both patients developed hidradenitis suppurativa after varying durations of leflunomide therapy.
- Symptomatic improvement of hidradenitis suppurativa was noted within weeks of leflunomide discontinuation.
Findings:
- Leflunomide therapy was associated with the onset of hidradenitis suppurativa in two rheumatoid arthritis patients.
- Discontinuation of leflunomide led to clinical improvement of the hidradenitis suppurativa symptoms.
- This suggests a potential causal link between leflunomide and hidradenitis suppurativa development.
Implications:
- Physicians should consider leflunomide as a potential cause of hidradenitis suppurativa in patients with rheumatoid arthritis.
- Monitoring for skin conditions like HS is important during leflunomide treatment.
- Further research may be warranted to elucidate the mechanism of drug-induced HS by leflunomide.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
399
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
399
01:29Drugs for Treatment of Ulcerative Colitis in IBD
383
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
383
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
356
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
356
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
389
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
389
01:26Nephrotic Syndrome II : Assessment and Medical Management
152
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
152
01:17Drugs for Treatment of Diarrhea-Predominant IBS
537
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
537